{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "RLYB",
  "name": "Rallybio Corporation",
  "url": "https://frontierpicks.com/dossiers/RLYB/",
  "json_url": "https://frontierpicks.com/dossiers/RLYB.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "No new filing since the 2026-08-06 10-Q: as of 2026-08-23 the 2026-07-15 S-4 is still not effective, with no record date or meeting date set. The 2026-08-21 close of $16.83 sits ~7% above the ~$15.68/share implied by the S-4's $83.2M Net Cash over 5,306,894 shares — the discount has inverted, and the clock keeps adding burn.",
  "invalidation_trigger": "A weekly close below $14 breaks the read — that sits under the per-share arithmetic on the S-4's $83.2M Net Cash at 2026-06-30 and implies the market is pricing a deal break or a Net Cash haircut. Secondary: the 2026-07-15 registration statement still not declared effective by 2026-09-30.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "precision-biotech-therapeutics",
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "2026-06-01: Reverse merger w/ private Avenzo Therapeutics + $215M PIPE; combined co. Rebrands AVZO, closes Q4 2026. Legacy RLYB = cash distribution + 1 CVR/share (REV102/Recursion + legacy assets) + 2.8% stub ($15M implied vs Avenzo $300M / financing $215M).",
    "2026-06-01: All-stock reverse merger with private Avenzo Therapeutics + $215M oversubscribed concurrent PIPE; combined co. Rebrands Avenzo, trades as AVZO, expected close Q4 2026. Boards unanimously approved.",
    "2026-03-01: merger agreement with Candid Therapeutics. 2026-05-03: Candid terminated to accept a UCB deal (Candid acquired by UCB for up to $2.2B). 2026-05-04: Rallybio paid $50.0M parent termination fee + $0.4M expense reimbursement.",
    "2026-06-01: all-stock reverse merger with private Avenzo Therapeutics + $215M oversubscribed concurrent PIPE. Combined co rebrands Avenzo Therapeutics, trades AVZO, expected close Q4 2026.",
    "1-for-8 reverse split effective 2026-02-06 for Nasdaq compliance; 5,306,894 shares outstanding at 2026-06-30 per the Q2 10-Q.",
    "Headline exits are not assured.",
    "Post-close the company is renamed Avenzo Therapeutics and trades as AVZO; legacy holders retain ~2.8% plus one non-transferable CVR per share.",
    "The CVR is non-transferable and pays only where legacy-asset and Recursion proceeds clear a $1M minimum threshold, through 2031-12-31.",
    "The 0.5020 exchange ratio adjusts on final Net Cash and share count at closing, so the 2.8% legacy stake is not fixed.",
    "No record date or special-meeting date is public as of 2026-08-23; the meeting is due within 45 calendar days of S-4 effectiveness."
  ],
  "body_markdown": "## Current Thesis\nNothing has entered the public file since the **2026-08-06 10-Q**. As of **2026-08-23** the **Form S-4 filed 2026-07-15** has not been declared effective, no amendment to it appears in the public filing record, and no record date or special-meeting date exists. Thirty-nine days of SEC calendar have passed with the docket quiet.\n\nSo the situation stands where the last two filings left it. The S-4 carries **Rallybio Net Cash of approximately $83.2M at 2026-06-30**, down from **~$87.7M at 2026-03-31**. The 10-Q carries **$92.8M cash and equivalents, $98.1M total assets, $3.6M total liabilities and 5,306,894 shares outstanding** at the same date, with **Q2 net income of $43.7M** on the **$50.0M Candid Therapeutics termination fee** received 2026-05-04 against a **$5.7M Q2 operating loss** and **$14.4M for the first half**.\n\nDividing the S-4 figure by the 10-Q share count gives roughly **$15.68 per share** — arithmetic on two filed numbers, not a disclosed distribution amount. The **2026-08-21 close of $16.83** sits about 7% above that, with the 52-week high at **$17.00**. What a buyer is paying for above the cash line is the CVR, the 2.8% Avenzo stub and the assumption that the deal closes without a Net Cash haircut. The pile itself no longer comes at a discount.\n\n## Bull Case\n- **The pile is unlevered and disclosed.** 10-Q 2026-08-06: $92.8M cash against $3.6M total liabilities, with no marketable securities left to mark — the $23.4M held at 2025-12-31 matured during the period.\n- **The distribution mechanism is written down.** The 2026-07-15 S-4 specifies \"Parent Distributions\" of substantially all Net Cash to pre-closing securityholders, with **up to $50M declarable before the stockholder meeting**.\n- **The CVR window is five years.** One non-transferable CVR per pre-closing share, entitling holders pro rata to net proceeds from legacy-asset dispositions and Recursion payments **through 2031-12-31**, subject to a **$1M minimum distribution threshold**.\n- **A quiet docket is consistent with a light review.** No S-4/A has been filed in the 39 days since 2026-07-15. That is an inference about SEC comment traffic, not a disclosure — but the shorter path to the 45-calendar-day meeting clock runs through no re-filing.\n- **Financing was the smallest variable and remains so.** The **$215.0M concurrent private placement announced 2026-06-01** was described as oversubscribed, with Blackstone Multi-Asset Investing, accounts advised by T. Rowe Price Investment Management, Vivo Capital, OrbiMed, Affinity Asset Advisors and ADAR1 Capital Management.\n- **Break protection is asymmetric.** Avenzo owes **$20.0M** on certain terminations (**$8.0M** after the End Date) plus up to $750K expenses, against $600K flowing the other way. This board already banked a **$50.0M** break fee on 2026-05-04 when Candid walked to UCB.\n- **Stub terms are fixed at the top of the document:** Avenzo at **$300.0M**, Rallybio at **$15.0M** post-distribution, exchange ratio **0.5020**, pro forma ownership **56.6% Avenzo / 40.6% financing / 2.8% legacy**. Clinical anchor: **AVZO-021 (selective CDK2) at ASCO 2026-06-01 — 5.3-month median PFS in HR+/HER2− patients with a median of four prior lines**, with the financing stated to fund operations into late 2028.\n\n## Bear Case\n- The May–June discount is gone.\n- **Net Cash decays into the close.** The company's own estimate stepped down **$4.5M** between the 3/31/26 and 6/30/26 marks. A close \"prior to the end of 2026\" implies two more quarterly steps plus transaction, legal and wind-down costs before anything is distributed.\n- **The distribution is capped and conditional.** Per the S-4, only one Parent Distribution may occur before the stockholder meeting, capped at **$50M declared pre-meeting**, and the final amount may be lower or zero.\n- **Every downstream date floats.** No effectiveness order, no record date, no meeting notice as of 2026-08-23. The meeting is due within **45 calendar days of effectiveness**, so a September effectiveness pushes the vote toward late October and the close into the last weeks of the year.\n- **The 2.8% is not fixed.** The 0.5020 exchange ratio adjusts on final Net Cash and share count at closing, so both the cash return and the stub move with the same variable.\n- Any adverse 8-K reprices this in a gap.\n\n## Setup & Price Structure\n- **Reference prices:** last completed daily close **$16.83 (2026-08-21)**; 52-week high **$17.00**; **-1.0%** from that high; **RSI(14) 66.5**; a three-month price change of **+6.0%**.\n- **Drift, not trend.** From **$16.99 on 2026-08-14** to $16.83 on 2026-08-21 is about 1% over five sessions while the registration clock ran. Price is pinned near the top of its range with no new information arriving.\n- **The narrative is maturing.** The informational peak was **2026-07-15** (S-4 Net Cash) and **2026-08-06** (10-Q balance sheet); the last press headline is **2026-06-01**, 83 days back. The name still works — within 1% of the 52-week high — but the flow that re-rated it from a sub-cash quote is spent, and the marginal buyer is now underwriting completion rather than discovering a discount. It flips to saturated if this shelf holds into October with no effectiveness order, because at that point the premium is being paid purely for elapsed time.\n- **Positioning observables.** Three Schedule 13G/A ownership amendments are dated **2026-08-14** in the public filing record; that is the standard 45-day post-quarter deadline, so their timing is a calendar artifact. Director Helen M. Boudreau's **Form 4 filed 2026-07-10** reports an exercise of **3,562 options at $2.38 on 2026-07-06**, taking reported holdings to **6,542 shares**, with no sale disclosed alongside it. There is no imminent earnings print — the next 10-Q is due around 2026-11-10. Rallybio itself has issued no equity into the move; the $215.0M placement sits at the Avenzo level and is priced with the deal.\n- **Structure of the payoff.** Upside is bounded by the document — cash near the $15.68 arithmetic, plus a CVR with a $1M threshold and a 2.8% stub carried at $15.0M — while a termination reopens the whole range below. RSI in the mid-60s at a 52-week high in a name whose upside is capped by filed arithmetic is momentum without a numerator.\n\n## Catalyst Calendar (next 30 days)\n- **~2026-09-15 (est.)** — SEC declaring the 2026-07-15 Form S-4 effective. No date is set as of 2026-08-23. This is the gate on every other date.\n- **Any date, unscheduled** — a Form S-4/A amendment. If the SEC has issued comments, the amendment is the first visible artifact; none has appeared in 39 days.\n- **~2026-09-22 (est.)** — record date and special-meeting notice, reachable inside the window only if effectiveness lands by mid-September.\n- Outside the 30-day window but on the same chain: **~2026-10-31 (est.)** special meeting with a possible pre-vote Parent Distribution declaration; **~2026-11-10 (est.)** Q3 10-Q with the next disclosed Net Cash mark; **2026-12-31** as the outer edge of the stated expectation to close before year-end.\n\n## What Would Change Our Mind\nThe clock breaks first. If 2026-09-30 arrives with the 2026-07-15 registration statement still not effective and no meeting notice on file, a Q4 close stops being the base case and each additional quarter subtracts burn from the distributable pile — the disclosed step between 3/31/26 and 6/30/26 was $4.5M.\n\nThe second break is the number itself. A declared Parent Distribution materially below the **$83.2M** reference, or a meeting held with no distribution declared, removes the arithmetic the current price leans on. So would a Q3 10-Q Net Cash mark stepping down by more than $4.5M.\n\nOn price, **a weekly close below $14** ends the read: that level sits under the per-share arithmetic on the S-4's $83.2M at 2026-06-30 and would say the market is discounting a break or a haircut rather than a completion.\n\nImprovement runs the other way and is equally observable: an effectiveness order plus a declared distribution at or near the June-30 mark restores a defined floor under the price and turns the remaining exposure into the CVR and the stub alone.\n\n## Correlation Notes\n- While the deal is pending, this should not behave like biotech beta. The quote is anchored to a filed cash figure, so co-movement with XBI/IBB ought to be weak; the shared factor is deal-completion risk and the Q4 2026 biotech financing window in which the $215.0M placement has to fund.\n- **Recursion (RXRX) is the readable proxy for the CVR.** REV102-related payments flow from Recursion, so its pipeline prioritisation disclosures are the observable that carries information about whether the CVR ever clears the $1M threshold.\n- Post-close the correlation set changes wholesale. As AVZO the security becomes a clinical-stage CDK-inhibitor and bispecific-ADC oncology story trading with that cohort's data cycle, and the 2.8% legacy stake inherits whatever first-float discount reverse-merger listings take.\n- Within the merger-arbitrage complex, the comparable is any cash-shell reverse merger where the pre-deal quote has closed its discount to net cash before the vote; the group's shared risk is a financing environment that reprices between signing and closing.",
  "first_seen": "2026-05-07",
  "last_analyzed": "2026-08-23T16:35:46+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}